Study Stopped
Class I Recall (Feb 2026): Boston Scientific issued a global recall for specific lots of AXIOS 6x8mm and 8x8mm due to reports of deployment and expansion failure during the procedure.
EUS-guided Choledochoduodenostomy vs ERCP as First Line in Malignant Distal Obstruction (CARPEDIEM Trial)
Endoscopic Ultrasound-Guided Biliary Drainage With Lumen-Apposing Stent vs Classical ERCP for First-line Therapy of Malignant Distal Biliary Obstruction: An Open-label, Multicenter Randomized Trial (CARPEDIEM Trial)
1 other identifier
interventional
120
1 country
10
Brief Summary
The aim of this clinical trial is to evaluate the biliary drainage technical failure rate and/or the postprocedure acute pancreatitis rate between EUS-CDS vs ERCP procedures in patients with distal malignant biliary obstruction.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for not_applicable
Started May 2025
Typical duration for not_applicable
10 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
October 19, 2024
CompletedFirst Posted
Study publicly available on registry
October 22, 2024
CompletedStudy Start
First participant enrolled
May 6, 2025
CompletedPrimary Completion
Last participant's last visit for primary outcome
June 6, 2027
ExpectedStudy Completion
Last participant's last visit for all outcomes
May 6, 2028
May 6, 2026
May 1, 2025
2.1 years
October 19, 2024
May 2, 2026
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Postprocedure surgical challenges rate
Percentage of biliary drainage technical failure and/or percentage of postprocedure acute pancreatitis.
1 day to 24 months
Secondary Outcomes (5)
Clinical success
14 days after BD
AE - biliary drainage
0 to 30 days after BD
AE - surgery
0 to 90 days after surgery
Delay in days between endoscopic biliary drainage and cephalic duodenopancreatectomy (CDP)
1 day to 6 months
Rate of surgery
1 to 24 months
Study Arms (2)
ERCP with SEMS
ACTIVE COMPARATOREndoscopic retrograde cholangiopancreatography (ERCP) with deployment of a self-expandable metallic stent (SEMS). Gold standard in malignant distal biliary obstruction (MDBO) in current practice. ERCP technique: Cannulation with papillotome (advanced cannulation techniques are allowed). Sphincterotomy. Self-expandable metallic stent (SEMS) deployment.
EUS-CDS with LAMS-Pigtail
EXPERIMENTALEchoendoscopy-guided Choledochoduodenostomy (EUS-CDS) with deployment of a lumen-apposing metal stent (LAMS) and axis-orienting double-pigtail plastic stent throug LAMS. EUS-CDS technique: Diagnostic EUS. Classic or free-hand with preloaded guidewire choledochoduodenostomy with LAMS. Pneumatic dilation whithin LAMS is allowed. In case of bile duct \< 15mm is mandatory the 'push' technique. Deployment of a pigtail coaxial to LAMS.
Interventions
Decompression of the bile duct by endoscopic aproach.
Self-expandable metallic stent (SEMS) deployment: Covering: Uncovered or Partially Covered. Non covered if gallbladder is present. Size: 10x40mm or 10x60mm or 10x80mm.
Lumen-apposing metal stent (LAMS) with coaxial double-pigtail plastic stent (DPPS) deployment: LAMS size: 6x8mm or 8x8mm. Consider 10x10mm if bile duct \> 18mm. DPPS size: 7Fr x 3-7cm.
Eligibility Criteria
You may qualify if:
- Malignant distal biliary obstruction diagnosed in patient considered RESECTABLE or POTENTIALLY RESECTABLE/BORDERLINE with biliary drainage indication: i) impaired hepatic enzymes (including hyperbilirubinemia) x3 times upper the superior normal value. ii) Radiologic singns of extrahepatic bile duct obstruction with presence of retrograde dilatation, of at least 12-mm axial diameter.
- Consensual malignancy by a bilio-pancreatic multidisciplinar committe (histological confirmation is not mandatory)
- Patient capable of understanding and/or singning the informed consent.
- Patient who understands the type of study and will comply with all follow-up tests throughout its duration
You may not qualify if:
- Pregnancy or lactation.
- Severe coagulation disorder: INR \> 1.5 non correctable with plasma administration and/or platelet count \< 50.000/mm3.
- Distal malignant biliary strictures in patients considered directly resectable, non-surgical, unresectable, or palliative
- Benign or uncertain etiology of biliary strictures or strictures located proximally or in close proximity to the hilum.
- Patients with prior biliary stents or other biliary drainages (e.g., PTCD).
- Altered intestinal anatomy due to prior surgery that prevents or hinders papillary access (e.g., gastric bypass, Billroth II, duodenal switch, Roux-en-Y).
- Stenosis in the antral or duodenal region that prevents access to the duodenum and reaching the papilla.
- Situations that do not allow for upper gastrointestinal endoscopy (e.g., esophageal stricture).
- Patients with functional diversity, who lack the capacity to understand the nature and potential consequences of the study, except when a legal representative is available.
- Patients incapable of maintaining follow-up appointments (lack of adherence).
- Lack of informed consent.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Hospital Universitari de Bellvitgelead
- Hospital Mutua de Terrassacollaborator
- Hospital Clínico Universitario de Valenciacollaborator
- Hospital General Universitario de Alicantecollaborator
- Hospital General Universitario de Castellóncollaborator
- Complejo Hospitalario Universitario de Santiagocollaborator
- University Hospital Virgen de las Nievescollaborator
- Hospital de Sant Paucollaborator
- University of Salamancacollaborator
- Complejo Hospitalario de Navarracollaborator
Study Sites (10)
Hospital General Universitario Dr. Balmis
Alicante, Alicante, 03010, Spain
Hospital General Universitario de Castellón
Castellon, Castellón, 12004, Spain
Hospital de Sant Pau i de la Santa Creu
Barcelona, Catalonia, 08041, Spain
Hospital Universitari de Bellvitge
Hospitalet de Llobregat, Barcelona, Catalonia, 08907, Spain
Hospital Mútua de Terrassa
Terrassa, Catalonia, 08221, Spain
Hospital Clínico Universitario de Santiago
Santiago de Compostela, Galicia, 15706, Spain
Hospital Universitario Virgen de las Nieves
Granada, Granada, 18014, Spain
Complejo Hospitalario de Navarra
Pamplona, Navarre, 31006, Spain
Hospital Clínico Universitario de Salamanca
Salamanca, Salamanca, 37007, Spain
Hospital Clínico Universitario de Valencia
Valencia, Valencia, 46010, Spain
Related Publications (5)
Teoh AYB, Napoleon B, Kunda R, Arcidiacono PG, Kongkam P, Larghi A, Van der Merwe S, Jacques J, Legros R, Thawee RE, Saxena P, Aerts M, Archibugi L, Chan SM, Fumex F, Kaffes AJ, Ma MTW, Messaoudi N, Rizzatti G, Ng KKC, Ng EKW, Chiu PWY. EUS-Guided Choledocho-duodenostomy Using Lumen Apposing Stent Versus ERCP With Covered Metallic Stents in Patients With Unresectable Malignant Distal Biliary Obstruction: A Multicenter Randomized Controlled Trial (DRA-MBO Trial). Gastroenterology. 2023 Aug;165(2):473-482.e2. doi: 10.1053/j.gastro.2023.04.016. Epub 2023 Apr 28.
PMID: 37121331RESULTJanet J, Albouys J, Napoleon B, Jacques J, Mathonnet M, Magne J, Fontaine M, de Ponthaud C, Durand Fontanier S, Bardet SSM, Bourdariat R, Sulpice L, Lesurtel M, Legros R, Truant S, Robin F, Prat F, Palazzo M, Schwarz L, Buc E, Sauvanet A, Gaujoux S, Taibi A. Pancreatoduodenectomy Following Preoperative Biliary Drainage Using Endoscopic Ultrasound-Guided Choledochoduodenostomy Versus a Transpapillary Stent: A Multicenter Comparative Cohort Study of the ACHBT-FRENCH-SFED Intergroup. Ann Surg Oncol. 2023 Aug;30(8):5036-5046. doi: 10.1245/s10434-023-13466-8. Epub 2023 Apr 17.
PMID: 37069476RESULTChen YI, Sahai A, Donatelli G, Lam E, Forbes N, Mosko J, Paquin SC, Donnellan F, Chatterjee A, Telford J, Miller C, Desilets E, Sandha G, Kenshil S, Mohamed R, May G, Gan I, Barkun J, Calo N, Nawawi A, Friedman G, Cohen A, Maniere T, Chaudhury P, Metrakos P, Zogopoulos G, Bessissow A, Khalil JA, Baffis V, Waschke K, Parent J, Soulellis C, Khashab M, Kunda R, Geraci O, Martel M, Schwartzman K, Fiore JF Jr, Rahme E, Barkun A. Endoscopic Ultrasound-Guided Biliary Drainage of First Intent With a Lumen-Apposing Metal Stent vs Endoscopic Retrograde Cholangiopancreatography in Malignant Distal Biliary Obstruction: A Multicenter Randomized Controlled Study (ELEMENT Trial). Gastroenterology. 2023 Nov;165(5):1249-1261.e5. doi: 10.1053/j.gastro.2023.07.024. Epub 2023 Aug 6.
PMID: 37549753RESULTBarbosa EC, Santo PADE, Baraldo S, Nau AL, Meine GC. EUS- versus ERCP-guided biliary drainage for malignant biliary obstruction: a systematic review and meta-analysis of randomized controlled trials. Gastrointest Endosc. 2024 Sep;100(3):395-405.e8. doi: 10.1016/j.gie.2024.04.019. Epub 2024 Apr 20.
PMID: 38648989RESULTGopakumar H, Singh RR, Revanur V, Kandula R, Puli SR. Endoscopic Ultrasound-Guided vs Endoscopic Retrograde Cholangiopancreatography-Guided Biliary Drainage as Primary Approach to Malignant Distal Biliary Obstruction: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Am J Gastroenterol. 2024 Aug 1;119(8):1607-1615. doi: 10.14309/ajg.0000000000002736. Epub 2024 Feb 29.
PMID: 38421018RESULT
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Intervention Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Joan B Gornals, PhD
Hospital Universitari de Bellvitge, SEED
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- SINGLE
- Who Masked
- OUTCOMES ASSESSOR
- Purpose
- TREATMENT
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- PhD and Head of Interventional Endoscopy Unit
Study Record Dates
First Submitted
October 19, 2024
First Posted
October 22, 2024
Study Start
May 6, 2025
Primary Completion (Estimated)
June 6, 2027
Study Completion (Estimated)
May 6, 2028
Last Updated
May 6, 2026
Record last verified: 2025-05